Syringe and Vial Shielding in Nuclear Medicine

Syringe and vial shields are the first and most-used engineering control for occupational dose in nuclear medicine — but because photon attenuation is energy-specific, the shield that protects a technologist from Tc-99m can be nearly transparent to F-18. A 2 mm tungsten shield stops the great majority of 140 keV photons yet barely attenuates 511 keV annihilation photons, which need 5 to 8 mm of tungsten to matter. Getting material and thickness right — and knowing where shields help the fingertips least — is core radiation-safety physics.¹²

Hand and whole-body dose in nuclear medicine is dominated by the handling of unsealed radiopharmaceuticals: drawing doses, purging air, injecting patients, and disposing of syringes. The exposure of the fingers is one of the field's principal radiation-protection concerns, and the highest finger doses occur at the fingertip during preparation and dispensing of F-18 for diagnostics and Y-90 for therapy.¹ Shields are the front line of defense, but only if they are chosen for the radionuclide and used within a broader time-distance-shielding program.

This guide explains the attenuation physics behind shield selection, why tungsten has displaced lead for PET, how thick a shield each common nuclide needs, the important limits of shields at the fingertips, and the regulatory framework for extremity dose. DRPS supports hot-lab and radiation-safety programs through radiation safety officer consulting across Florida, Maryland, Virginia, Washington DC, California, Nevada, and our other service areas.

Introduction

Every unsealed dose a technologist handles is an external radiation source held centimeters — sometimes millimeters — from the skin. Because dose rate falls with the square of distance and rises with activity, the hands are the most-exposed tissue in most nuclear medicine departments, and the fingertips most of all.¹

Shielding attacks the problem at the source. A syringe shield is a tube of dense metal, usually with a leaded-glass or tungsten window, that surrounds the barrel of the syringe; a vial shield is a pot that surrounds the stock vial. Both reduce the photon fluence reaching the worker. But shielding is a physics problem, not a one-size-fits-all product: the attenuation a given thickness provides depends steeply on the photon energy of the radionuclide, and the same shield performs very differently for a 140 keV emitter and a 511 keV emitter.²

This guide follows the physics from the attenuation equation through material choice and thickness to the practical, sometimes counterintuitive reality that a syringe shield does far more for the whole body and eye lens than for the fingertips actively manipulating the dose.

Topic Explanation

What a shield does — and the material choice

A syringe or vial shield reduces the external photon dose rate by attenuating photons in a dense, high-atomic-number material before they reach tissue. The two properties that make a good shield are high density (more electrons per centimeter to interact with) and high atomic number (more photoelectric absorption at lower energies). Lead (Z = 82, density ≈ 11.3 g/cm³) has been the traditional choice. Tungsten (Z = 74, density ≈ 19.3 g/cm³) is now standard for PET because its much higher density delivers the same attenuation in a thinner, less bulky shield — and a thinner shield preserves the dexterity that keeps handling fast and safe.²

Tungsten shields are typically tungsten-impregnated composites or sintered tungsten. They are non-toxic to handle, unlike bare lead, and their compactness is a genuine ergonomic and safety advantage for high-energy work. For the stock vial, a vial shield — often a tungsten or lead pot with a leaded-glass window — plays the same role while the multidose vial sits on the bench and during draws. These source shields work alongside benchtop L-blocks and dose-draw workstations, and together they define the hot lab's engineered dose control, as discussed in nuclear medicine hot lab design.

Energy is everything

The central fact of shield selection is that attenuation is energy-dependent. Tc-99m emits a 140 keV gamma ray; I-123 emits 159 keV; Lu-177 emits a 208 keV imaging photon; and F-18 produces two 511 keV annihilation photons. As energy rises, photons penetrate more, photoelectric absorption (which scales steeply with Z and inversely with energy) fades, and Compton scattering dominates. The practical consequence is that a shield sized for a low-energy nuclide can be almost transparent to a high-energy one.² This is why the shielding conversation for PET is fundamentally different from the one for a conventional Tc-99m clinic, a theme that also runs through occupational dose from PET 511 keV photons.

Key Technical Principles

The attenuation equation

For a narrow beam of monoenergetic photons, the transmitted fraction $B$ through a shield of thickness $x$ and linear attenuation coefficient $μ$ is:

B = \frac{I}{I _{0}} = e^{- μx}

The linear attenuation coefficient is the product of the mass attenuation coefficient $(μ / ρ)$ and the material density $ρ$ :

μ = (\frac{μ}{ρ}) ρ

Both $(μ / ρ)$ and therefore $μ$ fall as photon energy rises, which is why the same thickness transmits far more at 511 keV than at 140 keV. Radionuclide-specific attenuation and lead-shielding values are tabulated in standard references for over a thousand radionuclides.⁹

Worked example: Tc-99m versus F-18 through tungsten

Using approximate NIST-derived narrow-beam mass attenuation coefficients for tungsten ( $ρ = 19.3 g/cm^{3}$ ):

Tc-99m at 140 keV, $(μ / ρ) \approx 1.9 cm^{2} / g$ , so $μ \approx 1.9 \times 19.3 \approx 36.7 cm^{- 1}$ . For a 2 mm (0.2 cm) shield:

B = e^{- (36.7) (0.2)} = e^{- 7.3} \approx 6.7 \times 1 0^{- 4}

That is better than 99.9% attenuation — which is why roughly 2 mm of tungsten or lead is more than sufficient for Tc-99m.²

F-18 at 511 keV, $(μ / ρ) \approx 0.11 cm^{2} / g$ , so $μ \approx 0.11 \times 19.3 \approx 2.08 cm^{- 1}$ . For that same 2 mm shield:

B = e^{- (2.08) (0.2)} = e^{- 0.42} \approx 0.66

Only about 34% attenuation — the 2 mm shield is nearly transparent. To get a meaningful reduction, increase the thickness:

B_{5 mm} = e^{- (2.08) (0.5)} = e^{- 1.04} \approx 0.35 (\sim 65% reduction)

B_{8 mm} = e^{- (2.08) (0.8)} = e^{- 1.66} \approx 0.19 (\sim 81% reduction)

This is exactly why shielding of about 5 mm, and preferably 8 mm, of tungsten is commonly recommended for F-18 work, while 2 mm suffices for Tc-99m.¹²

Why tungsten beats lead at 511 keV

Compare an 8 mm shield of each material for F-18. Using approximate NIST-derived coefficients:

Material	Density (g/cm³)	Approx. μ at 511 keV (cm⁻¹)	Transmission through 8 mm	Approx. transmission through 2 mm (140 keV)
Tungsten	19.3	≈ 2.08	≈ 0.19 (81% reduction)	< 0.001 (>99.9% reduction)
Lead	11.35	≈ 1.15	≈ 0.40 (60% reduction)	≈ 0.002 (>99% reduction)

At 511 keV, 8 mm of tungsten (transmission ≈ 0.19) clearly outperforms 8 mm of lead (≈ 0.40), so a tungsten shield achieves the same protection in less thickness and bulk. At 140 keV both materials are highly effective at 2 mm. (Values are approximate, narrow-beam, and energy-dependent; broad-beam buildup makes real transmission somewhat higher, so shields are engineered conservatively.)²

The fingertip problem: shields help the hands least where it matters most

Here is the counterintuitive part. A syringe shield surrounds the barrel and protects the palm, the whole body, and the eye lens well — but during active manipulation the fingertips are often at the unshielded ends of the syringe (the needle hub and the plunger), and they touch or nearly touch the source. Published work shows syringe shields have limited effectiveness during actual manipulation, and the fingertip consistently receives the highest extremity dose.¹

Compounding this, the standard ring dosimeter is worn at the base of the finger, where it can underestimate the true fingertip dose by a factor of roughly 1.4 to 7.¹ So the tissue at greatest risk is both the least protected by the shield and the least accurately monitored by the standard dosimeter. This is why shielding must be paired with distance (forceps and tongs), minimized handling time, dose-draw and automated injection systems, and — for the highest-activity work — workflow redesign. These themes carry through our guides to extremity dosimetry in nuclear medicine and time, distance, and shielding for external dose.

Clinical Impact

Shield selection has a measurable effect on occupational dose. In a clinical study of one technologist performing 100 F-18 FDG procedures, viewing-window tungsten-shielded syringes reduced the measured whole-body dose relative to unshielded syringes — from about 13.8–14.3 µSv per 370 MBq (unshielded) to 7.2–10.7 µSv per 370 MBq (shielded), an effective-dose reduction on the order of 25%; extrapolated to 725 examinations per year, the estimated annual dose fell from roughly 10 mSv (unshielded) to 7.5 mSv (shielded). The same study measured a right-hand dose near 69 µSv per 370 MBq even with shielded syringes, underscoring that the hands remain the dose-limiting tissue.³

For a busy PET service, the difference between correct 8 mm tungsten shielding and inadequate low-energy shielding is the difference between a comfortable dose margin and approaching regulatory limits over a year. For therapy nuclides such as Lu-177 and Y-90, where administered activities are far higher, shielding must be combined aggressively with distance and workflow controls, because no practical hand shield alone can offset a high-activity source held close.¹

The takeaway for interpretation and program design is consistent: shields protect the whole body and eye lens effectively when energy-matched, but the fingertips need a layered strategy. Treating "we use syringe shields" as sufficient for hand-dose control is a common and consequential error.

Practical Optimization Tips

Match the shield to the radionuclide

Use 5–8 mm tungsten for F-18 and other 511 keV / high-energy work. A 2 mm shield sized for Tc-99m is nearly transparent to annihilation photons.¹²
2 mm tungsten or lead is adequate for Tc-99m and similar low-energy emitters (140–170 keV).
For Lu-177, I-131, and Y-90, select shielding for the imaging/gamma component and, critically, lean on distance and workflow because activities are high and, for Y-90, bremsstrahlung must also be considered.

Protect the fingertips deliberately

Maximize distance with tools. Long forceps or tongs for high-activity draws move the fingertips off the source, which the inverse-square law rewards more than any incremental shield thickness.
Minimize handling time. Rehearse and streamline draws; pre-drawn or unit doses and automated dose-draw/injection systems remove the hand from the highest-dose steps.
Wear dosimetry that reflects reality. Position the ring dosimeter as close to the fingertip / most-exposed area as practical, per program guidance, recognizing base-of-finger placement underestimates fingertip dose.¹

Build shielding into the workflow, not just the syringe

Use vial shields, benchtop L-blocks with leaded glass, and dose-draw workstations so the source is shielded at every idle moment, not only during the draw.
Keep unshielded contact incidental and brief; never rest a bare syringe or vial on the open bench.
Combine shielding with contamination control; skin contamination can dominate extremity dose and is addressed in nuclear medicine decontamination best practices.

Common pitfalls to avoid

Using a Tc-99m-era shield for PET. The most common and most costly mistake.
Assuming the shield protects the fingertips as well as it protects the palm and body.
Trusting a base-of-finger ring dose as the true fingertip dose.
Neglecting distance and time because "we have shields."
Leaving vials and syringes unshielded between steps.

Regulatory Considerations

Extremity and whole-body dose from handling radiopharmaceuticals is governed by NRC or Agreement-State radiation-protection rules, and shielding is the primary engineering control a program uses to stay within them.

Dose limits. Under 10 CFR 20.1201, the occupational limit for total effective dose equivalent is 5 rem (50 mSv) per year, and the shallow-dose-equivalent limit to the skin of the extremities is 50 rem (500 mSv) per year.⁴
Monitoring. Under 10 CFR 20.1502, monitoring of the extremities is required when a worker is likely to receive, in one year, a dose exceeding 10% of the applicable limit — so extremity (ring) dosimetry is required for most technologists handling therapeutic activities and many handling diagnostic F-18.⁵
Medical-use program. Handling, safety procedures, and the radiation safety officer's responsibilities fall under 10 CFR Part 35 and the licensing guidance in NUREG-1556 Volume 9; ALARA expectations under 10 CFR 20.1101 make shielding, distance, and time part of the required program.⁶⁷
Radiation-protection framework. ICRP Publication 103 provides the system of protection — justification, optimization, and dose limitation — that underlies the U.S. limits and the ALARA principle.⁸
State and Agreement-State jurisdiction. Of the states DRPS serves, Florida, Maryland, Virginia, California, and Nevada are NRC Agreement States (Florida under Chapter 64E-5, F.A.C.), while Washington DC and Delaware are regulated directly by the NRC. Confirm which authority issues your license and which monitoring and recordkeeping requirements apply.

Documented shield selection, extremity-monitoring records, and an ALARA review of handling practices are what make a hot-lab radiation-safety program defensible during inspection. See our guides to occupational eye lens dose and extremity dosimetry in nuclear medicine for the monitoring side of the program.

Frequently Asked Questions (FAQs)

Why are tungsten syringe shields preferred over lead for PET?

Tungsten is much denser than lead (about 19.3 versus 11.3 grams per cubic centimeter), so it attenuates the 511 keV annihilation photons of F-18 in a thinner, less bulky shield. A thinner shield is easier to manipulate, which matters because dexterity affects both handling time and the risk of a dropped or fumbled dose. Tungsten is also non-toxic to handle compared with bare lead, so tungsten and tungsten-composite shields have become standard for PET syringes and vials.

How thick does a syringe shield need to be for Tc-99m versus F-18?

It depends entirely on photon energy. For technetium-99m (140 keV), roughly 2 mm of tungsten or lead attenuates the great majority of photons. For F-18 (511 keV annihilation photons), that same 2 mm is nearly transparent; shielding of about 5 mm, and preferably 8 mm, of tungsten is commonly recommended to achieve a meaningful reduction. The higher the photon energy, the thicker the shield required for the same attenuation.

Do syringe shields protect the fingertips?

Only partially, and less than many assume. Syringe shields reduce dose to the palm, whole body, and eye lens, but during active manipulation the fingertips are often close to unshielded portions of the syringe (the needle end and plunger), and published work shows shields have limited effectiveness during actual manipulation. The fingertip typically receives the highest extremity dose, and a ring dosimeter worn at the base of the finger can underestimate the fingertip dose by a factor of roughly 1.4 to 7.

What is the annual dose limit for the hands and extremities?

Under 10 CFR 20.1201, the occupational shallow-dose-equivalent limit to the skin of the extremities is 50 rem (500 mSv) per year, separate from the 5 rem (50 mSv) total effective dose equivalent limit. Extremity monitoring is required under 10 CFR 20.1502 when a worker is likely to receive more than 10% of the applicable limit. Nuclear medicine hand doses can approach these levels without good shielding, distance, and technique.

Are vial shields different from syringe shields?

They serve the same purpose but for the stock vial rather than the drawn dose. A vial shield (often a tungsten or lead pot with a leaded-glass viewing window) protects the technologist while a multidose vial sits on the bench and during draws. Because the vial holds more activity than a single syringe, vial shielding, benchtop L-blocks, and dose-draw workstations all contribute to reducing whole-body and hand dose in the hot lab.

Does a syringe shield eliminate the need for other radiation protection?

No. Shielding is one leg of the time-distance-shielding triad. Shields must be combined with minimizing handling time, maximizing distance (long forceps or tongs for high-activity sources), using dose-draw and injection systems where available, contamination control, and proper dosimetry. For high-activity therapy nuclides such as Lu-177 or Y-90, workflow and distance often matter as much as the shield itself.

Key Takeaways

Energy decides thickness. About 2 mm of tungsten or lead handles Tc-99m (140 keV); F-18 (511 keV) needs about 5–8 mm of tungsten for meaningful attenuation.¹²
Tungsten beats lead for PET. Its higher density gives the same attenuation in a thinner, less bulky, non-toxic shield.²
Shields protect the body and eye lens more than the fingertips. During manipulation the fingertips are near unshielded syringe ends and receive the highest dose.¹
Standard ring dosimetry underestimates the fingertip. By a factor of roughly 1.4 to 7 when worn at the base of the finger.¹
Correct shielding measurably lowers dose. Shielded F-18 syringes reduced whole-body dose on the order of 25% in a clinical study, but the hands remained dose-limiting.³
Shielding is one leg of the triad. Combine it with time, distance, workflow, contamination control, and monitoring to meet the 10 CFR 20 limits.⁴⁵

Conclusion

Syringe and vial shields are the most familiar radiation-protection tools in nuclear medicine, but their effectiveness is not a fixed property of the product — it is a function of photon energy, material, thickness, and how the source is actually handled. A shield chosen for Tc-99m is inadequate for F-18; tungsten's density makes it the material of choice at 511 keV; and no shield fully protects the fingertips that manipulate the dose. The programs that control occupational dose best treat shielding as physics, not inventory: they match the shield to the radionuclide, pair it with distance and workflow, monitor the extremities where the dose actually is, and document the choices. Done that way, shielding keeps the hardest-working tissue in the department — the technologist's hands — well within safe limits.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and PET programs turn shielding physics into practical, documented radiation safety. Our support includes radiation safety officer consulting, hot-lab and workflow review, shield-selection and dose-rate assessments, extremity-monitoring program design, ALARA evaluations, and radiation safety training for staff, delivered by board-certified medical physicists. We also provide PET/CT and nuclear medicine physics support across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong hot-lab program is not just about owning shields. It is about proving the shields are matched to the nuclide and paired with the distance, time, and monitoring that protect the hands.

Related Resources

References

Kollaard R, Zorz A, Dabin J, et al. Review of extremity dosimetry in nuclear medicine. Journal of Radiological Protection. 2021;41(4). doi:10.1088/1361-6498/ac31a2. doi.org
National Institute of Standards and Technology. XCOM: Photon Cross Sections Database (mass attenuation coefficients for tungsten and lead). nist.gov
Biran T, Weininger J, Malchi S, Marciano R, Chisin R. Measurements of occupational exposure for a technologist performing 18F FDG PET scans. Health Physics. 2004;87(5):539-544. doi:10.1097/01.hp.0000137180.85643.9d. doi.org
U.S. Nuclear Regulatory Commission. 10 CFR 20.1201: Occupational dose limits for adults. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 20.1502: Conditions requiring individual monitoring of external and internal occupational dose. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Program-Specific Guidance About Medical Use Licenses. nrc.gov
International Commission on Radiological Protection. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. Annals of the ICRP. 2007;37(2-4). icrp.org
Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health Physics. 2012;102(3):271-291. doi:10.1097/HP.0b013e318235153a. PubMed